Core Viewpoint - The potential reclassification of marijuana by President Trump could significantly impact Aurora Cannabis and the broader marijuana industry, making it easier for businesses to operate and increasing demand for cannabis products [3][4]. Group 1: Legislative Changes - President Trump is expected to issue an executive order to reclassify marijuana from Schedule I to Schedule III, which could occur as early as January [3]. - This reclassification would not legalize marijuana outright but would facilitate business operations within the industry, aligning cannabis more closely with prescription drugs [3]. Group 2: Financial Implications - The reclassification would likely lead to banks being more willing to extend loans and accept deposits from marijuana businesses, enhancing the financial landscape for companies like Aurora Cannabis [4]. - Companies would also benefit from being able to deduct more expenses from their income taxes, potentially increasing legal demand for marijuana products [4]. Group 3: Market Performance - Aurora Cannabis stock experienced a significant increase of 14.5% following the positive news regarding marijuana legalization [1]. - Despite the optimistic market reaction, Aurora Cannabis has struggled with profitability, continuing to report losses even in a legal market like Canada since 2018 [6][7].

Core Viewpoint - Cannabis stocks, including Tillray and Aurora, are experiencing significant gains due to reports that the president plans to reclassify marijuana to a less dangerous category, potentially moving it from Schedule I to Schedule III, similar to Tylenol with codeine [1][2] Group 1: Reclassification Process - The president is reportedly drafting an executive order to advise the DOJ and DEA to proceed with the reclassification, which could be issued as soon as Monday [2] - Following the executive order, the DOJ and DEA will publish a final rule, which will then enter a 30-day waiting period for any challenges, indicating potential delays due to opposition [4] Group 2: Industry Perspectives - Tillray's CEO, Irwin Simon, expresses optimism about the reclassification, believing that there will be significant changes by the end of the year, marking a departure from previous false starts [3] - A cannabis lawyer suggests that this reclassification could signal the beginning of a new era in public health policy, although it is viewed as a partial victory with ongoing legalization and regulatory challenges ahead [5] Group 3: Implications of Reclassification - The reclassification is not equivalent to legalization but is expected to facilitate medical research on cannabis, which could lead to broader acceptance and potential future legalization at the federal level [6][8] - The industry hopes that increased medical use will eventually pave the way for more recreational cannabis products, especially in light of recent legislative actions like the hemp ban [8]

Core Viewpoint - Cannabis stocks experienced a significant surge, with Tilray Brands (TLRY.US) rising over 32%, Canopy Growth (CGC.US) increasing over 23%, SNDL (SNDL.US) up over 19%, Aurora Cannabis (ACB.US) gaining over 11%, and Cronos Group (CRON.US) climbing over 5% due to reports that President Donald Trump is considering reclassifying cannabis to a lower harm category [1] Group 1 - Tilray Brands (TLRY.US) saw an increase of over 32% [1] - Canopy Growth (CGC.US) rose by more than 23% [1] - SNDL (SNDL.US) experienced a gain of over 19% [1] Group 2 - Aurora Cannabis (ACB.US) increased by more than 11% [1] - Cronos Group (CRON.US) rose by over 5% [1] - Reports indicate that Trump is considering moving cannabis from Schedule I to Schedule III, indicating a potential shift in regulatory stance [1]

Core Viewpoint - The stock prices of major cannabis companies surged significantly following reports of President Trump's plans to relax federal regulations on marijuana, with notable increases in premarket trading [1][2]. Group 1: Stock Price Movements - Tilray Brands (NASDAQ:TLRY) saw a price increase of 34.88%, while Canopy Growth (NASDAQ:CGC) rose by 27.46% in premarket trading [1]. - Other companies also experienced substantial gains: Aurora Cannabis Inc. (NASDAQ:ACB) surged 20%, Cronos Group Inc. (NASDAQ:CRON) gained 19%, Organigram Global Inc. (NASDAQ:OGI) rose 12%, and SNDL Inc. (NASDAQ:SNDL) increased by 34.7% [1]. Group 2: Regulatory Changes - The surge in stock prices was attributed to news that Trump plans to instruct federal agencies to reclassify marijuana as a Schedule III drug, which would change its regulatory status [2][3]. - This reclassification would subject cannabis companies to different tax regulations, potentially attracting more investments and placing marijuana in the same category as substances like steroids and Tylenol with codeine [3]. Group 3: Historical Context - Trump had previously hinted at this reclassification in August, indicating a consistent approach towards cannabis regulation [3]. - The anticipated change is expected to occur early next year, moving marijuana from a category that includes heroin to a lower tier for less dangerous substances [4].

Core Viewpoint - The potential reclassification of cannabis by President Trump from Schedule I to Schedule III is expected to significantly benefit the cannabis industry, leading to a surge in stock prices for major cannabis producers in the U.S. [1][2] Group 1: Market Reaction - Major cannabis producers saw substantial stock price increases in pre-market trading, with Tilray Brands (TLRY.US) rising over 30%, Canopy Growth (CGC.US) up 23%, Aurora Cannabis (ACB.US) increasing by 20%, SNDL (SNDL.US) gaining 14%, and Cronos Group (CRON.US) up 12% [1] - The market response indicates strong investor optimism regarding the potential regulatory changes surrounding cannabis [1] Group 2: Regulatory Context - President Trump is considering moving cannabis from Schedule I, which indicates no medical use and high abuse potential, to Schedule III, which includes substances with accepted medical uses but some potential for abuse [1][2] - Schedule III drugs include substances like ketamine and anabolic steroids, while Schedule I includes LSD and heroin [2] - The Biden administration previously proposed a similar reclassification in March 2024, but the DEA canceled related hearings [2] Group 3: Political and Industry Implications - Trump's discussions with key officials and cannabis industry executives suggest a serious consideration of the reclassification, which could alleviate criminal penalties for personal use and remove certain federal tax and business barriers [2] - The reclassification could improve the operating environment for legal cannabis businesses and their employees [2] - Robert F. Kennedy Jr., nominated by Trump for the Department of Health and Human Services, has advocated for ending cannabis criminalization and implementing a regulated sales system [3]

Core Insights - US-listed cannabis stocks experienced significant premarket gains on Friday due to reports indicating a potential shift in federal marijuana policy under President Donald Trump [1] Group 1: Market Reaction - The cannabis sector saw a revival in investor interest following the news of possible changes in federal policy [1] - The premarket gains suggest a positive market sentiment towards cannabis stocks amid the evolving regulatory landscape [1]

Core Insights - Aurora Cannabis Inc. has launched a new proprietary cultivar named Black Jelly in Poland, enhancing its portfolio of high-potency medical cannabis products in a rapidly growing European market [1][2] - Black Jelly features a cannabinoid profile of THC 27% and CBD <1%, and is derived from a high-THC sativa strain [2] - The company emphasizes its advanced genetic breeding program and cultivation excellence as key factors in successfully introducing this product to the Polish market [2][3] Product Details - Black Jelly is characterized by dense, large flowers with green and orange hues, and a terpene profile that includes sweet black liquorice and fruity undertones [2] - The product is grown and manufactured in Aurora's Canadian facilities that are certified under GACP and EU-GMP standards [1][2] Market Position - Aurora Cannabis continues to strengthen its leadership in the international medical cannabis sector, leveraging scientific expertise and regulatory knowledge to support patient access and market growth across Europe [3] - The company has over a decade of experience in global medical markets, positioning itself as a trusted partner in advancing Poland's medical cannabis ecosystem [3] Company Overview - Aurora Cannabis operates in both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a diverse brand portfolio [4] - The company also holds a controlling interest in Bevo Farms Ltd., a leading supplier of propagated agricultural plants in North America [5]

Here Is How Reform Will Help Most Marijuana Stocks In The MarketWith 2026 showing to be a big year for reform, how will this impact marijuana stocks? Looking back over the years, it is clear that marijuana stocks have seen their best trading when positive news on reform is released. The speculation of what could happen drives the market action up often. If investors feel the reform is important enough, you’ll then see some increased buying action.What many know already is the long, grueling, intense volatil ...

Core Insights - Aurora Cannabis Inc. has appointed Kerry Miller as Managing Director for Australia and New Zealand, effective January 15, 2026, to drive growth in these markets [1][2] Group 1: Leadership Appointment - Kerry Miller brings 35 years of experience in consumer packaged goods, with a notable 25-year tenure at Reckitt Benckiser and nearly 10 years at Unilever, where he led global initiatives and transformation programs [3] - Miller expressed enthusiasm about joining Aurora at a pivotal moment for the company, focusing on expanding access to medical cannabis and enhancing innovation and partnerships [2] Group 2: Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Canada, serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand [4] - The company offers a diverse portfolio of brands, including adult-use brands like Drift and San Rafael '71, and medical brands such as MedReleaf and CanniMed [4] - Aurora also holds a controlling interest in Bevo Farms Ltd., a major supplier of propagated agricultural plants in North America [4]

Core Insights - Aurora Cannabis Inc. has announced a distribution partnership with Leafio to enhance access to medical cannabis for patients in Australia [1][2] - The partnership aims to provide educational resources for healthcare professionals and improve patient outcomes through a reliable supply chain [2][5] Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Canada, serving both medical and consumer markets across multiple regions including Canada, Europe, Australia, and New Zealand [3] - The company offers a diverse portfolio of brands, including MedReleaf, CanniMed, and Whistler Medical Marijuana Co., and is focused on high-quality cannabis products [3] Partnership Details - The agreement allows Leafio to distribute Aurora's medical cannabis products through its nationwide supply chain, which services over 4,000 pharmacies in Australia [2][5] - The partnership is expected to enhance research, product innovation, and clinician education, ultimately benefiting the medical cannabis industry in the region [2][6] Market Impact - This collaboration is positioned to significantly improve access to consistent, high-quality medical cannabis for Australian patients [2][6] - The partnership reflects Aurora's commitment to expanding its leadership in the Australian market and enhancing patient access to medical cannabis [2][6]